IL-22 promotes the progression of breast cancer through regulating HOXB-AS5.

Jiang Rui,Gao Binbin,Zhao Chunming,Wang Shengxi,Shao Na,Song Wei

doi:10.18632/oncotarget.22063

Jiang Rui, Gao Binbin + Show 4 more

Open Access

https://doi.org/10.18632/oncotarget.22063

Copy DOI

Journal: Oncotarget	Publication Date: Oct 19, 2017
Citations: 24	License type: cc-by

Affiliation: Shandong Provincial Hospital

Abstract

Interleukin-22 (IL-22) is a well-known tumor related inflammatory factor that is associated with variety of cancers. HOXB-AS5, a long non-coding RNA located in HOX gene clusters, has been elevated in breast cancer (BC) tissues. Herein, IL-22 and HOXB-AS5 were upregulated in the serum and tissues of BC patients and were associated with clinical stages. Furthermore, we also investigated the effects of IL-22-HOXB-AS5 pathway on progression of BC, and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-mTOR pathway. These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.

Highlights

Breast cancer (BC) is the most common cancer and is the principal cause of cancer death among females worldwide [1]
We investigated the effects of IL-22-HOXB-AS5 pathway on progression of breast cancer (BC), and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-Mammalian target of the rapamycin (mTOR) pathway
These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC

Summary

Introduction

Breast cancer (BC) is the most common cancer and is the principal cause of cancer death among females worldwide [1]. Interleukin-22 (IL-22), formally referred to as IL-10-related T cell-derived inducible factor (ILTIF), belongs to the IL-10 family and is released from immune cells, including several types of CD4+ and CD8+ T lymphocytes, γδ T lymphocytes, natural killer T (NKT) cells and group 3 ILCs [5, 6]. IL-22 binds to the heterodimer formed by the IL-10 receptor b (IL-10Rb) and the IL-22 receptor (IL-22R) to induce differentiation [5, 6]. IL-10Rb is widely expressed on the human cell surface, while IL-22R expression is limited to epithelial cells, but not immune cells [5, 6].

Methods

Findings

Discussion

Conclusion